Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

When On­colo­gie launched last year, it high­light­ed its trendy mod­el of op­er­at­ing be­tween Boston and Shang­hai amid a wave of Chi­nese cap­i­tal ea­ger to back ex­pe­ri­enced US ex­ecs in de­vel­op­ing West­ern can­cer drugs for the Asian mar­ket. For its Se­ries B, it’s al­ly­ing it­self with an­oth­er buzzy con­cept in the in­dus­try — choos­ing the right pa­tients by bio­mark­ers.

Nan Fung Life Sci­ences and Piv­otal BioVen­tures Chi­na came back to lead the $80 mil­lion round de­signed to speed up clin­i­cal de­vel­op­ment as well as ramp­ing up part­ner­ing and ac­qui­si­tion of new as­sets, ac­cord­ing to CEO Lau­ra Ben­jamin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.